# AXIFI Clinical Intelligence

> AI-powered clinical research platform with 257 clinical documents, 19 blog articles, protocols, case studies, and research articles.
> Last Updated: 2026-06-01

## About

AXIFI is a comprehensive knowledge platform for clinical research. It provides access to clinical research, treatment protocols, case studies, and an AI research assistant (AXIFI) trained on the full corpus of clinical research literature.

The platform covers:
- Peptide therapeutics (BPC-157, GHK-Cu, Thymosin, DSIP, and more)
- Exosome therapy and cellular communication
- Hormone optimization and metabolic balance
- PRP (Platelet-Rich Plasma) therapy
- Integrative clinical research approaches

## Key Pages

- [Homepage](https://www.axifi.ai/): Overview of the research platform
- [Research Library](https://www.axifi.ai/library): Full searchable library of clinical documents
- [AI Research Assistant](https://www.axifi.ai/chat): Chat with AXIFI AI for instant research answers
- [Search](https://www.axifi.ai/search): Search across all documents and therapies

## Therapy Categories

- [Metabolic & GLP-1 Therapies](https://www.axifi.ai/metabolic-glp1): GLP-1 receptor agonists, dual and triple agonists, oral GLP-1 formulations, amylin analogs, metabolic peptides, and prescription weight management agents targeting insulin sensitivity, appetite regulation, body composition, and metabolic longevity.
- [Longevity & Anti-Aging](https://www.axifi.ai/longevity-anti-aging): Senolytics, mTOR inhibitors, epigenetic compounds, telomere biology agents, caloric restriction mimetics, polyamines, and longevity vitamins that target the hallmarks of aging to extend healthspan and biological resilience.
- [Peptide Blends & Stacks](https://www.axifi.ai/peptide-blends-stacks): Purpose-built multi-peptide formulations and curated stacking protocols combining synergistic compounds for healing, performance, longevity, cognitive enhancement, and aesthetic outcomes.
- [Supplements & Nutraceuticals](https://www.axifi.ai/supplements): Evidence-graded vitamins, minerals, adaptogens, amino acids, polyphenols, anti-inflammatory compounds, omega fatty acids, and methylation support nutrients that form the nutritional foundation of longevity and precision health.
- [PRP & PRF Therapies](https://www.axifi.ai/prp-prf): Platelet-rich plasma and platelet-rich fibrin protocols for orthopedic injury repair, aesthetic skin rejuvenation, hair restoration, sexual health enhancement, and advanced PRF membrane applications.
- [Exosome Therapies](https://www.axifi.ai/exosome-therapies): Extracellular vesicle-based therapies delivered systemically via IV, orthopedic injection, aesthetic application, hair follicle targeting, sexual health regeneration, and intranasal routes for CNS access.
- [Growth Hormone Secretagogues](https://www.axifi.ai/growth-hormone-secretagogues): GHRH analogs, GHRP-class peptides, oral GH secretagogues, and recombinant growth hormone compounds that stimulate endogenous GH release, supporting body composition, recovery, sleep quality, and anabolic signaling.
- [Stem Cell Therapies](https://www.axifi.ai/stem-cell-therapies): Autologous and allogeneic stem cell protocols, perinatal tissue therapies, and combined cellular approaches targeting tissue regeneration, immune modulation, and systemic anti-aging through cellular replenishment.
- [Cognitive Enhancement & Nootropics](https://www.axifi.ai/cognitive-nootropics): Cholinergics, racetams, peptide nootropics, cognitive adaptogens, wakefulness agents, neuroprotective compounds, and medicinal mushroom extracts that enhance memory, focus, processing speed, and long-term brain resilience.
- [Sports Medicine & Performance](https://www.axifi.ai/sports-medicine-performance): Injury recovery peptides, muscle preservation agents, SARMs, endurance compounds, ergogenics, sports IV protocols, and sleep-recovery optimization for athletes and high-performance individuals.
- [Combination Protocols](https://www.axifi.ai/combination-protocols): Curated multi-therapy protocol stacks combining peptides, hormones, regenerative compounds, and devices into structured clinical programs targeting longevity, metabolic health, cognitive performance, sports recovery, and aesthetic outcomes.
- [NAD+ & Mitochondrial Support](https://www.axifi.ai/nad-mitochondrial): NAD+ precursors, mitochondrial antioxidants, biogenesis activators, mitophagy inducers, and energy substrate compounds that restore cellular energy production, reduce oxidative stress, and support healthy aging at the mitochondrial level.
- [Sexual Health & Optimization](https://www.axifi.ai/sexual-health): Therapies targeting libido and desire, erectile function, female sexual health, hormonal sexual optimization, and regenerative sexual health interventions including PRP, peptides, and shockwave protocols.
- [Peptides](https://www.axifi.ai/peptides): Therapeutic peptides spanning healing and regenerative, anti-inflammatory, immune-modulating, antimicrobial, cardioprotective, and neuroprotective mechanisms — the foundational compound class of precision medicine.
- [Bioregulators (Khavinson Peptides)](https://www.axifi.ai/bioregulators): Short-chain peptide bioregulators derived from the Khavinson research lineage, targeting thymic, pineal, neuro, vascular, and organ-specific restoration of tissue-specific gene expression and biological age.
- [Hormone Optimization](https://www.axifi.ai/hormone-optimization): Evidence-based hormonal optimization protocols spanning androgens, estrogens, progestogens, thyroid hormones, adrenal hormones, and peptide hormones — calibrated to restore physiological balance and peak function.
- [IV Therapy](https://www.axifi.ai/iv-therapy): Intravenous infusion protocols delivering nutritional, antioxidant, metabolic-longevity, oxidative, neuromodulatory, chelation-detox, and custom formulations directly into circulation for rapid bioavailability and systemic effect.
- [Ozone Therapy](https://www.axifi.ai/ozone-therapy): Medical ozone protocols spanning systemic major autohemotherapy, localized joint and wound application, rectal and vaginal insufflation, transdermal ozone, combined ozone-UBI protocols, and prolozone regenerative injections.
- [Regenerative Injection Therapies](https://www.axifi.ai/regenerative-injections): Prolotherapy, perineural injection therapy, neural therapy, micro-fragmented adipose tissue (MFAT), viscosupplementation, and intradiscal PRP protocols for joint, nerve, and disc regeneration.
- [Device & Energy Therapies](https://www.axifi.ai/device-energy-therapies): PEMF, red light and photobiomodulation, hyperbaric oxygen (HBOT), cryotherapy, sauna and heat therapy, shockwave and ultrasound, neurostimulation, electrical stimulation, mechanical pressure, and altitude-hypoxic conditioning devices.
- [Aesthetic Injectables](https://www.axifi.ai/aesthetic-injectables): Neurotoxins, hyaluronic acid fillers, biostimulators, permanent fillers, thread lifts, fat-dissolving compounds, bio-revitalization agents, and facial mesotherapy protocols for non-surgical aesthetic enhancement.
- [Laser & Energy Skin Treatments](https://www.axifi.ai/laser-energy-skin): Ablative and fractional laser resurfacing, IPL and broadband light, RF microneedling, HIFU ultrasound, body contouring devices, pigment and vascular lasers, and laser hair removal systems.
- [Hair Restoration](https://www.axifi.ai/hair-restoration): PRP and PRF hair protocols, exosome hair treatment, low-level laser therapy (LLLT) for hair, prescription and OTC hair medications, hair transplant adjuncts, and targeted scalp treatment programs.
- [Skin Peptides & Cosmeceuticals](https://www.axifi.ai/skin-cosmeceuticals): Topical peptides, growth factors, retinoids, vitamin C derivatives, collagen synthesis activators, skin-targeted nutraceuticals, and mesotherapy compounds for evidence-based dermal rejuvenation.
- [Emerging Therapies](https://www.axifi.ai/emerging-therapies): Pipeline GLP-1 variants, next-generation senolytics, gene therapy applications, epigenetic reprogramming agents, and novel peptides and compounds entering clinical evidence in 2025-2026.
- [Supplements & Vitamins](https://www.axifi.ai/supplements-vitamins): Evidence-based supplements and vitamins form the accessible foundation of any longevity protocol.
- [Herbal & Botanical Medicine](https://www.axifi.ai/herbal-botanical): Herbal and botanical medicine bridges thousands of years of traditional healing with modern scientific validation.
- [Biohacking & Wellness Protocols](https://www.axifi.ai/biohacking-wellness-protocols): Biohacking and wellness protocols encompass the rapidly growing field of evidence-informed self-optimization practices.
- [Regenerative Medicine](https://www.axifi.ai/regenerative-medicine): Regenerative medicine harnesses the bodys own biological systems to repair damaged tissues and restore function at the cellular level.

## Clinical Resources

- [Clinical Outcomes](https://www.axifi.ai/clinical/outcomes): Real-world clinical outcome tracking
- [Clinical Protocols](https://www.axifi.ai/clinical/protocols): Treatment protocol library

## Recent Research Documents

- [Humanin-G protects septic ARDS by mediating mitochondrial function in lung vascular endothelial cells.](https://www.axifi.ai/library/humanin-g-protects-septic-ards-by-mediating-mitochondrial-fu-42153337): Recent investigations show that mitochondrial impairment significantly contributes to endothelial damage in septic acute respiratory distress syndrome
- [American Society for Metabolic and Bariatric Surgery statement on the treatment options for patients with non-response and weight recurrence after metabolic and bariatric surgery.](https://www.axifi.ai/library/american-society-for-metabolic-and-bariatric-surgery-stateme-42150970): Metabolic and bariatric surgery (MBS) is the most effective treatment for severe obesity, producing durable weight loss and improvement in obesity-rel
- [Pharmacovigilance of semaglutide: A descriptive analysis of WHO-VigiAccess reports.](https://www.axifi.ai/library/pharmacovigilance-of-semaglutide-a-descriptive-analysis-of-w-42152320): Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is widely prescribed for type 2 diabetes mellitus and chronic weight management. With
- [Emerging Approaches for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease: The Application of Nanomedicines.](https://www.axifi.ai/library/emerging-approaches-for-the-treatment-of-metabolic-dysfuncti-42152979): Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global population, with limited pharmacological trea
- [Metabolic and nutritional stress-associated dilated cardiomyopathy in the setting of semaglutide use and long-term nicotine replacement therapy: a case report and literature review.](https://www.axifi.ai/library/metabolic-and-nutritional-stress-associated-dilated-cardiomy-42152984): Dilated cardiomyopathy (DCM) is a leading cause of heart failure and cardiac transplantation worldwide. It is a multifactorial condition with diverse 
- [Small-Molecule Oral Versus Injectable Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists: Comparative Efficacy, Safety, and Future Clinical Perspectives.](https://www.axifi.ai/library/small-molecule-oral-versus-injectable-glucagon-like-peptide-42153087): Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the management of type 2 diabetes (T2D), obesity, and cardiometabolic disease by
- [Association between HbA1c and breast cancer risk in women with type 2 diabetes mellitus: A case-control study.](https://www.axifi.ai/library/association-between-hba1c-and-breast-cancer-risk-in-women-wi-42152291): Type 2 diabetes mellitus (T2DM) has been linked to several types of cancer, including breast cancer. Glycated hemoglobin (HbA1c) serves as an indicato
- [Mechanistic Insights and Therapeutic Potential of MCC950 as a NLRP3 Inflammasome Inhibitor in Multiple Sclerosis: A Narrative Review.](https://www.axifi.ai/library/mechanistic-insights-and-therapeutic-potential-of-mcc950-as-42152629): The NLR family pyrin domain-containing 3 (NLRP3) inflammasome is a central driver of neuroinflammation and demyelination in multiple sclerosis (MS). M
- [Venoarterial extracorporeal membrane oxygenation as bridge support for refractory catecholamine-resistant shock and severe lactic acidosis in a patient with metformin exposure and multifactorial contributors: A case report.](https://www.axifi.ai/library/venoarterial-extracorporeal-membrane-oxygenation-as-bridge-s-42153113): A 47-year-old male with type 2 diabetes on metformin and hypertension presented with profound hypoxemia, severe metabolic acidosis (pH unrecordable, l
- [Association between metformin use and cervical cancer risk in women with diabetes in Japan: a retrospective cohort study.](https://www.axifi.ai/library/association-between-metformin-use-and-cervical-cancer-risk-i-42153174): This study aimed to evaluate the association between metformin use and the risk of cervical cancer in women with diabetes compared to dipeptidyl pepti
- [Type 2 diabetes and gynecologic cancers: Immunometabolic convergence and translational implications.](https://www.axifi.ai/library/type-2-diabetes-and-gynecologic-cancers-immunometabolic-conv-42153964): Type 2 diabetes mellitus (T2DM) is a highly prevalent chronic condition and an increasingly relevant host factor in cancer prevention, treatment, and 
- [Management of advanced HR-positive breast cancer using metabolically supported chemotherapy and repurposed drugs: a case report.](https://www.axifi.ai/library/management-of-advanced-hr-positive-breast-cancer-using-metab-42100430): Metastatic hormone receptor-positive (HR+) breast cancer is largely incurable once resistance to conventional treatments occurs. Emerging evidence sug
- [Multifunctional injectable hydrogel with Zn-metformin coordination for synergistic anti-infection, antioxidant, and osteogenic therapy in periodontitis.](https://www.axifi.ai/library/multifunctional-injectable-hydrogel-with-zn-metformin-coordi-42100000): Periodontitis, a chronic inflammatory disease induced by pathogenic microorganisms. Effective management requires the elimination of plaque biofilms, 
- [Investigating the research trajectory and future trends in type 2 diabetes mellitus and aging: a bibliometric analysis from 2009 to 2025 based on big data.](https://www.axifi.ai/library/investigating-the-research-trajectory-and-future-trends-in-t-42099527): The relationship between type 2 diabetes mellitus (T2DM) and aging has attracted growing scientific attention. Growing evidence suggests that T2DM is 
- [[The effect of geroprotectors on life expectancy: Mechanisms of action and clinical potential.].](https://www.axifi.ai/library/the-effect-of-geroprotectors-on-life-expectancy-mechanisms-o-42150021): The global increase in life expectancy and the growing proportion of elderly individuals have intensified the challenge of aging and age-related disea
- [Two Doses to ICU or When Lactate Equals Glucose: Life-Threatening Lactic Acidosis due to Metformin After Initiation of Semaglutide.](https://www.axifi.ai/library/two-doses-to-icu-or-when-lactate-equals-glucose-life-threate-42147805): Glucagon-like peptide 1 agonists have emerged as a promising treatment option for diabetes. As the prescription of these agents is rapidly increasing,
- [Diabetes and cancer: clinical implications for integrated metabolic-oncologic care.](https://www.axifi.ai/library/diabetes-and-cancer-clinical-implications-for-integrated-met-42147243): Diabetes mellitus and cancer are among the most prevalent non-communicable diseases worldwide and increasingly coexist in clinical practice. Epidemiol
- [Case Report: rapid progressive puberty in siblings with MC4R p. Arg165Gln: longitudinal follow-up and gonadotropin-releasing hormone agonist treatment.](https://www.axifi.ai/library/case-report-rapid-progressive-puberty-in-siblings-with-mc4r-42147117): Pathogenic variants in melanocortin-4 receptor (MC4R) are the most common cause of nonsyndromic monogenic obesity. However, links between MC4R-related
- [Impact of hypoglycemic regimens on cardiac recovery and quality of life after PCI in elderly AMI patients.](https://www.axifi.ai/library/impact-of-hypoglycemic-regimens-on-cardiac-recovery-and-qual-42147056): To investigate the impact of blood glucose control levels on cardiac function recovery and long-term prognosis in elderly patients with acute myocardi
- [Decoding the hallmarks of GLP-1RA weight-loss super-responders.](https://www.axifi.ai/library/decoding-the-hallmarks-of-glp-1ra-weight-loss-super-responde-42147968): Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have reshaped obesity treatment, yet weight-loss outcomes remain highly uneven in real-world care
- [GLP-1 Agonists in Orthopedic Surgery: A Narrative Review of Bone Health and Surgical Implications.](https://www.axifi.ai/library/glp-1-agonists-in-orthopedic-surgery-a-narrative-review-of-b-42147422): Glucagon-like peptide-1 (GLP-1) receptor agonists, commonly used for glycemic control in patients with type 2 diabetes and for weight loss in obese pa
- [Obesity Management: Pharmacotherapy.](https://www.axifi.ai/library/obesity-management-pharmacotherapy-42101582): Anti-obesity drugs should be offered as initial treatment of overweight and obesity for adults with weight-related comorbidities and for those at high
- [Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry.](https://www.axifi.ai/library/use-of-semaglutide-and-tirzepatide-in-rheumatic-and-musculos-42101387): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) such as semaglutide (SEM) and tirzepatide (TZP) were initially approved for type 2 diabetes mana
- [Semaglutide-associated Twiddler syndrome.](https://www.axifi.ai/library/semaglutide-associated-twiddler-syndrome-42100587): 52-year-old woman with cardiac sarcoidosis and a dual-chamber implantable cardioverter defibrillator (ICD) was treated with semaglutide for refractory
- [Tirzepatide vs. semaglutide for obesity, glycemic control, and cardiovascular outcomes: a narrative review of clinical trials.](https://www.axifi.ai/library/tirzepatide-vs-semaglutide-for-obesity-glycemic-control-and-42100257): Tirzepatide, a dual glucose-dependent insulinotropic polypeptide, (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, has emerged as an effect
- [Semaglutide 2.4 mg for Obese Patients with MASH: A Cost-Effectiveness Analysis from the Italian NHS Perspective.](https://www.axifi.ai/library/semaglutide-2-4-mg-for-obese-patients-with-mash-a-cost-effec-42099530): Metabolic dysfunction-associated liver disease (MASLD) and its progression to steatohepatitis (MASH) are highly prevalent among obese patients, contri
- [Feed-Forward Deep Neural Networks Predict Substrate-Specific Effects of Transporter Variants to Explain Drug Response Variability.](https://www.axifi.ai/library/feed-forward-deep-neural-networks-predict-substrate-specific-42104208): Genetic variants in drug transporter genes shape the interindividual variability in drug response. However, their functional interpretation has remain
- [Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control.](https://www.axifi.ai/library/metformin-inhibits-mitochondrial-complex-i-in-intestinal-epi-42103929): Metformin is a versatile biguanide drug primarily prescribed for type II diabetes. Despite its extensive use, the mechanisms underlying its clinical e
- [Efsubaglutide alfa added to metformin improves glycaemia with β-cell functional responses in type 2 diabetes: a randomised, double-blind, placebo-controlled, two-stage adaptive phase 2b/3 trial (SUPER 2).](https://www.axifi.ai/library/efsubaglutide-alfa-added-to-metformin-improves-glycaemia-wit-42103705): Efsubaglutide alfa, a long-acting humanised GLP-1 receptor agonist, was evaluated as add-on therapy to metformin in adults with type 2 diabetes. In an
- [Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis.](https://www.axifi.ai/library/currently-approved-and-future-regimens-for-metabolic-dysfunc-42142900): Metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD), has
- [Switching patterns of GLP-1 receptor agonists from 2018 to 2025 in the largest private healthcare network in Poland.](https://www.axifi.ai/library/switching-patterns-of-glp-1-receptor-agonists-from-2018-to-2-42142150): To characterize switching among GLP-1 receptor agonists (GLP-1 RAs) in a large private-sector cohort in Poland and to quantify therapy- and patient-le
- [Irisin Mitigates Diabetic Cardiac Damage and Is Associated with Improved Redox Status and Reduced p53/VCAM-1 mRNA Expression in STZ-Treated Rats.](https://www.axifi.ai/library/irisin-mitigates-diabetic-cardiac-damage-and-is-associated-w-42103133): Diabetic cardiomyopathy is driven by oxidative stress, impaired myocardial enzyme function, and inflammatory/apoptotic signaling. Irisin has emerged a
- [Real-world Impact of GLP-1 Receptor Agonists on Health-related Quality of Life in Type 2 Diabetes and Obesity (SEVERAL Study).](https://www.axifi.ai/library/real-world-impact-of-glp-1-receptor-agonists-on-health-relat-42103575): To evaluate the real-world impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on health-related quality of life (HRQoL) and metabolic out
- [Targeting UXS1-Dependent Glucuronate Detoxification Potentiates Metformin's Anti-Tumor Efficacy in Lung Adenocarcinoma.](https://www.axifi.ai/library/targeting-uxs1-dependent-glucuronate-detoxification-potentia-42107063): Despite the widely reported experimental anti-tumor effects, metformin's role remains exceedingly complex, with contradictory results in clinical tria
- [Incretin-Based Anti-obesity Medications in Polycystic Ovary Syndrome: The Evidence Map.](https://www.axifi.ai/library/incretin-based-anti-obesity-medications-in-polycystic-ovary-42106472): Polycystic ovary syndrome (PCOS) is a common, heterogeneous condition that is tightly linked to obesity, visceral adiposity and insulin resistance. Li
- [Approach to the diagnosis and treatment of polycystic ovarian syndrome in adolescent patients.](https://www.axifi.ai/library/approach-to-the-diagnosis-and-treatment-of-polycystic-ovaria-42105324): Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders affecting women of reproductive age. Its diagnosis during adolescence i
- [Efficacy of pharmacological and nutritional interventions for glucose dysfunction in schizophrenia-A systematic review and network meta-analysis.](https://www.axifi.ai/library/efficacy-of-pharmacological-and-nutritional-interventions-fo-42104950): Individuals with schizophrenia experience disproportionately high rates of impaired glucose tolerance and insulin resistance. While pharmacological st
- [Semaglutide and Cardiovascular Outcomes in People with Type 2 Diabetes: A SUSTAIN-6 Post Hoc Analysis by Weight Loss Category.](https://www.axifi.ai/library/semaglutide-and-cardiovascular-outcomes-in-people-with-type-42105046): Type 2 diabetes (T2D) is a known risk factor for cardiovascular (CV) disease. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutid
- [Multi-Omics and network-based exploration of potential molecular pathways in heart failure relevant to left bundle branch pacing response heterogeneity: Immune remodeling, hub gene identification, and drug repurposing hypotheses.](https://www.axifi.ai/library/multi-omics-and-network-based-exploration-of-potential-molec-42113804): Left bundle branch pacing (LBBP) has gained increasing attention as a novel pacing strategy, but its molecular underpinnings in the context of heart f
- [Survival and Recurrence With GLP-1 Receptor Agonists in Breast Cancer.](https://www.axifi.ai/library/survival-and-recurrence-with-glp-1-receptor-agonists-in-brea-42113513): Patients with breast cancer (BC) with comorbid obesity or type 2 diabetes (T2D) experience poorer survival. Glucagon-like peptide-1 receptor agonists 
- [Effects of Semaglutide on Dumping Syndrome and Reactive Hypoglycemia After Bariatric Surgery: A Systematic Review and Meta-Analysis.](https://www.axifi.ai/library/effects-of-semaglutide-on-dumping-syndrome-and-reactive-hypo-42140745): Dumping syndrome and reactive hypoglycemia are common complications after bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB). Semaglutide
- [Novel regulatory SNPs that can be activated due to metformin treatment may orchestrate liver gluconeogenesis and add to the variability in AMPK-dependent mechanisms of metformin response.](https://www.axifi.ai/library/novel-regulatory-snps-that-can-be-activated-due-to-metformin-42111789): Metformin is a first-line therapy for type 2 diabetes, yet individual response varies significantly, with over 30 % of patients failing to achieve opt
- [Controversial effects of metformin on human physiology and pathophysiology.](https://www.axifi.ai/library/controversial-effects-of-metformin-on-human-physiology-and-p-42110530): Metformin is the first-line oral antihyperglycemic agent for type 2 diabetes mellitus (T2DM), with over 150 million individuals worldwide receiving tr
- [Effectiveness of Nutritional Therapy Versus Alpha-Glucosidase Inhibitors in Postprandial Glycemia Control in an Indian Subpopulation of Patients With Type 2 Diabetes: A Prospective Crossover Study.](https://www.axifi.ai/library/effectiveness-of-nutritional-therapy-versus-alpha-glucosidas-42110014): Type 2 diabetes mellitus (T2DM) poses a significant global health challenge, impacting millions of people worldwide. While many studies focus on HbA1c
- [Influence of Metformin on Exercise Metabolism and Capacity: A Systematic Review and Meta-Analysis.](https://www.axifi.ai/library/influence-of-metformin-on-exercise-metabolism-and-capacity-a-42139118): Metformin and exercise are often co-prescribed in adults with prediabetes and type 2 diabetes mellitus (T2DM). However, metformin may alter metabolic 
- [LKB1 Loss Sensitizes Lung Tumor Spheres to Mitomet-Induced Ferroptosis, and These Effects are Enhanced by mTOR Inhibition.](https://www.axifi.ai/library/lkb1-loss-sensitizes-lung-tumor-spheres-to-mitomet-induced-f-42138621): Owing to their robust antioxidant defense mechanisms, cancer stem-like cells (CSCs) maintain a low level of oxidative stress, which is crucial for pre
- [Combination of ivermectin and metformin promotes autophagy in MCF‑7 cells by inhibiting phosphorylation of the PI3K/AKT/mTOR pathway.](https://www.axifi.ai/library/combination-of-ivermectin-and-metformin-promotes-autophagy-i-42138203): Breast cancer remains one of the leading causes of cancer‑related mortality among women globally, necessitating the exploration of novel therapeutic s
- [Concurrent Metformin-Associated Lactic Acidosis and Euglycemic Diabetic Ketoacidosis Without Sodium-Glucose Cotransporter 2 Inhibitor Exposure: A Case Report and Literature Review.](https://www.axifi.ai/library/concurrent-metformin-associated-lactic-acidosis-and-euglycem-42137698): Metformin-associated lactic acidosis (MALA) and euglycemic diabetic ketoacidosis (euDKA) are distinct causes of high anion gap metabolic acidosis, but
- [Nine-Year Recurrence-Free Survival in Gastric Signet-Ring Cell Carcinoma: A Case Report of Laparoscopic Radical Resection Combining Long-Term Systematic Therapy and Metformin Enteric-Coated Tablets.](https://www.axifi.ai/library/nine-year-recurrence-free-survival-in-gastric-signet-ring-ce-42137612): Gastric signet-ring cell carcinoma (GSRCC) represents 10%-14% of all gastric malignancies. The overall prognosis for GSRCC is poorer compared to other
- [Impact of semaglutide on liver fibrosis score in people with HIV: findings from the CNICS cohort.](https://www.axifi.ai/library/impact-of-semaglutide-on-liver-fibrosis-score-in-people-with-42138385): Metabolic dysfunction-associated steatotic liver disease (MASLD) and liver fibrosis are key drivers of morbidity and mortality in people with HIV (PWH
- [Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance.](https://www.axifi.ai/library/unmasking-counterfeit-semaglutide-analysis-of-real-world-saf-42137313): The spread of counterfeit drugs represents a serious threat to public health because they may be ineffective or cause the onset of severe suspected ad
- [Improved Physical, Emotional, and Social Well-Being in People Living With Obesity Treated With Semaglutide: A Plain Language Summary.](https://www.axifi.ai/library/improved-physical-emotional-and-social-well-being-in-people-42110523): What is this summary about? Many people live with extra weight or obesity. Semaglutide is a type of weight loss medication for the treatment of obesit
- [Pharmacological targeting of the senescence-associated secretory phenotype in atherosclerosis: therapeutic potential of senolytics and senomorphics.](https://www.axifi.ai/library/pharmacological-targeting-of-the-senescence-associated-secre-42133066): Despite optimal lipid-lowering treatment, numerous older adults with atherosclerotic cardiovascular disease continue to experience progression driven 
- [EXPRESS: Metformin Exhibits Analgesic Activity in Neuronal Cell Models and CFA-Induced Inflammatory Pain in Mice.](https://www.axifi.ai/library/express-metformin-exhibits-analgesic-activity-in-neuronal-ce-42132331): Inflammatory pain is mediated by complex interactions between immune signaling and sensory neurons, with prostaglandin E2-dependent pathways playing a
- [Comparative Effectiveness of Individual Sodium Glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 2 Diabetes With Moderate Cardiovascular Risk: Emulation of a Target Trial.](https://www.axifi.ai/library/comparative-effectiveness-of-individual-sodium-glucose-trans-42132163): SGLT2 (sodium-glucose cotransporter 2) inhibitors reduce major adverse cardiovascular events (MACE) in type 2 diabetes. However, no direct comparison 
- [Antimicrobial and Synergistic Activity of Metformin Against Helicobacter pylori.](https://www.axifi.ai/library/antimicrobial-and-synergistic-activity-of-metformin-against-42131298): Helicobacter pylori (H. pylori) infection is highly prevalent worldwide and is associated with multiple gastroduodenal pathologies, including gastric 
- [Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation.](https://www.axifi.ai/library/glucagon-like-peptide-1-receptor-agonists-inhibit-the-initia-42133988): The aggregation of the 42-residue form of the amyloid-β peptide (Aβ42) is important in Alzheimer's disease (AD). Preclinical and clinical findings sup
- [Esophageal Motility Patterns Are Not Impacted By Glucagon-Like Peptide-1 Receptor Agonist Use.](https://www.axifi.ai/library/esophageal-motility-patterns-are-not-impacted-by-glucagon-li-42133868): Glucagon-like peptide-1 receptor agonist (GLP-1RA) use is associated with delayed gastric emptying. It is unknown whether GLP-1RAs affect esophageal m
- [Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by the North American Neuro-Ophthalmology Society and the American Academy of Ophthalmology.](https://www.axifi.ai/library/glucagon-like-peptide-1-receptor-agonists-and-the-risk-of-no-42132708): Recent studies have reported a possible association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and non-arteritic anterior ischemic 
- [Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities.](https://www.axifi.ai/library/glucagon-like-peptide-1-receptor-agonists-in-psoriasis-and-p-42131335): Psoriasis (PsO) and psoriatic arthritis (PsA) are chronic immune-mediated diseases often associated with obesity, metabolic syndrome, and type 2 diabe
- [Top studies of 2025 relevant to primary care: From the PEER team.](https://www.axifi.ai/library/top-studies-of-2025-relevant-to-primary-care-from-the-peer-t-42128641): To identify and summarize the most impactful medical articles published in 2025 relevant to primary care. The Patients, Experience, Evidence, Research
- [Timing and duration of glucagon-like peptide-1 receptor agonist use and risk of nonarteritic anterior ischaemic optic neuropathy.](https://www.axifi.ai/library/timing-and-duration-of-glucagon-like-peptide-1-receptor-agon-42126975): To investigate the association between glucagon-like peptide-1 receptor agonist (GLP-1RA) use and nonarteritic anterior ischaemic optic neuropathy (NA
- [Pharmacological interventions for the treatment of obesity in children and adolescents.](https://www.axifi.ai/library/pharmacological-interventions-for-the-treatment-of-obesity-i-42125960): Treating obesity in children and adolescents is complex, given the dynamic nature of growth and development during this life stage. The role of pharma
- [Formulation of Metformin-Loaded Chitosan Nanoparticles and In Vivo Evaluation of Its Hypoglycemic Effects.](https://www.axifi.ai/library/formulation-of-metformin-loaded-chitosan-nanoparticles-and-i-42123901): This study formulated and characterized metformin-loaded chitosan nanoparticles (NPs) using the ionic gelation technique and evaluated the drug releas
- [The Role of Antidiabetic Therapies in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review of Metformin, Pioglitazone, and GLP-1 Receptor Agonists.](https://www.axifi.ai/library/the-role-of-antidiabetic-therapies-in-mild-cognitive-impairm-42123553): Alzheimer's disease (AD) and mild cognitive impairment (MCI) are major causes of cognitive decline. Antidiabetic medications such as metformin, piogli
- [Adjunctive Non-Disease-Modifying Therapies in Multiple Sclerosis: Immunometabolic, Neuroprotective and Remyelination-Oriented Approaches.](https://www.axifi.ai/library/adjunctive-non-disease-modifying-therapies-in-multiple-scler-42123442): Disease-modifying therapies (DMTs) are the standard treatment for multiple sclerosis (MS) and effectively reduce inflammatory disease activity; howeve
- [Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.](https://www.axifi.ai/library/implications-of-glucagon-like-peptide-1-receptor-agonists-in-42126155): The number of patients taking glucagon-like peptide-1 receptor agonists (GLP-1RAs) is increasing. Beyond diabetes and weight management, these medicat
- [Baseline vitamin D status is associated with glycemic and weight loss outcomes in patients with type 2 diabetes treated with semaglutide.](https://www.axifi.ai/library/baseline-vitamin-d-status-is-associated-with-glycemic-and-we-42125318): Semaglutide, a glucagon-like peptide-1 receptor agonist, is an established therapy for type 2 diabetes (T2D), offering robust glycemic control and wei
- [Food-drug interactions of novel drugs used in cardiologic and diabetic patients - a PRISMA scoping review.](https://www.axifi.ai/library/food-drug-interactions-of-novel-drugs-used-in-cardiologic-an-42124949): Food-drug interactions are common in orally administered therapies. In order to achieve optimal therapeutic efficacy and safety, it is important for p
- [GLP-1 Receptor Agonist Combination Therapy Before and After Metabolic and Bariatric Surgery: A Review of Outcomes.](https://www.axifi.ai/library/glp-1-receptor-agonist-combination-therapy-before-and-after-42124784): The paradigm of obesity treatment is rapidly evolving with the introduction and widespread adoption of glucagon-like peptide-1 receptor agonists (GLP-
- [15-PGDH Inhibition Overcomes Muscle Regenerative Deficit Seen With GLP1-Receptor Agonist-Induced Weight Loss.](https://www.axifi.ai/library/15-pgdh-inhibition-overcomes-muscle-regenerative-deficit-see-42124647): Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including long-acting semaglutide, are revolutionary anti-obesity therapies. However, emerging 
- [Preliminary evidence of improved liver biomarkers in adolescents with obesity and suspected metabolic dysfunction-associated steatotic liver disease treated with semaglutide: A case series.](https://www.axifi.ai/library/preliminary-evidence-of-improved-liver-biomarkers-in-adolesc-42110146): Metabolic dysfunction-associated steatotic liver disease (MASLD) affects 30%-40% of youth with obesity and lacks approved pharmacologic therapies. In 
- [What obgyns need to know about GLP-1 receptor agonists.](https://www.axifi.ai/library/what-obgyns-need-to-know-about-glp-1-receptor-agonists-42108205): Obstetricians and gynecologists increasingly encounter patients using glucagon-like peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-depende
- [Role of the GAPDH-Mediated Glycolysis-Senescence Axis in Osteoarthritis Chondrocytes and Its Modulation by Semaglutide.](https://www.axifi.ai/library/role-of-the-gapdh-mediated-glycolysis-senescence-axis-in-ost-42107588): This study aimed to identify key regulatory genes involved in chondrocyte senescence in osteoarthritis (OA) and to evaluate the therapeutic potential 
- [Effectiveness of GLP-1 Receptor Agonists in Patients With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.](https://www.axifi.ai/library/effectiveness-of-glp-1-receptor-agonists-in-patients-with-po-42116999): Polycystic ovary syndrome (PCOS) is a complex endocrine-metabolic disorder, and while metformin is widely used in its management, its efficacy remains
- [Metformin and Phenformin Attenuate SARS-CoV-2 Spike Protein S1-Induced Endothelial Inflammation Involving AMPK/NF-κB Signaling in HUVECs.](https://www.axifi.ai/library/metformin-and-phenformin-attenuate-sars-cov-2-spike-protein-42116606): COVID-19, caused by SARS-CoV-2, is a systemic disease with vascular involvement. The spike protein subunit 1 (S1) has been suggested to contribute to 
- [Empagliflozin mitigates depression-like behavior in diabetic mice via putative CRF1 receptor modulation: behavioral, biochemical and in silico studies.](https://www.axifi.ai/library/empagliflozin-mitigates-depression-like-behavior-in-diabetic-42115393): Diabetes is one of the main cause and major risk factor for the development of neurodegenerative and neuropsychiatric disorders, including depression,
- [Subcutaneous injection of semaglutide causes increased muscle uptake of 18F-FDG and reduces the imaging quality of PET/CT: a case report.](https://www.axifi.ai/library/subcutaneous-injection-of-semaglutide-causes-increased-muscl-42118195): Semaglutide, a glucagon-like peptide-1 receptor agonist widely used in diabetes management, has not been previously reported to interfere with PET/CT 
- [Comparison of IBD-related outcomes in patients with obesity treated with GLP-1 receptor agonists versus bariatric surgery.](https://www.axifi.ai/library/comparison-of-ibd-related-outcomes-in-patients-with-obesity-42117113): The global prevalence of obesity is rising, paralleled by an increase in IBD (inflammatory bowel disease). While studies examining the impact of obesi
- [Transforming a protease inhibitor into a peptide Guardian: BBI-armed hydrogel beads for Oral delivery of active peptides.](https://www.axifi.ai/library/transforming-a-protease-inhibitor-into-a-peptide-guardian-bb-42116484): This study repurposes the Bowman-Birk inhibitor (BBI), traditionally viewed as an antinutritional factor for its protease inhibition, as a protective 
- [MASLD and MASLD-associated HCC: emerging biomarkers and therapeutic avenues.](https://www.axifi.ai/library/masld-and-masld-associated-hcc-emerging-biomarkers-and-thera-42115049): Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading chronic liver disease on a global scale. With its increasing incidence a
- [GLP-1 Dosing Protocols: Titration Strategies for Success](https://www.axifi.ai/library/glp1-dosing-titration-protocols-pplx-mo21f8r1): Complete guide to GLP-1 dosing schedules for semaglutide and tirzepatide — including titration charts, microdosing evidence, dose splitting rationale,
- [Revolutionizing Regenerative Medicine with Quantum Therapy](https://www.axifi.ai/library/quantum-cell-factor-comparison-moja9h2p): Quantum Therapy represents a significant advancement in regenerative medicine, outperforming traditional methods like PRP and stem cells. With its abi
- [A case report of postoperative poor drainage of perianal abscess in an obese diabetic patient treated with comprehensive therapy.](https://www.axifi.ai/library/a-case-report-of-postoperative-poor-drainage-of-perianal-abs-42100606): Postoperative inadequate drainage of perianal abscess is prevalent in obese patients with diabetes, caused by obesity-related high tissue pressure and
- [A pumpless liver-adipose model for studying metabolic dysfunction and drug responses.](https://www.axifi.ai/library/a-pumpless-liver-adipose-model-for-studying-metabolic-dysfun-42102059): Metabolic dysfunction is a primary driver of chronic diseases, such as obesity and type 2 diabetes. Developing in vitro models allows to understand me
- [Semaglutide Reverses Ectopic Lipid Accumulation, Impaired Myocardial Perfusion Reserve, and Diastolic Dysfunction in a Mouse Model of Cardiometabolic Heart Disease.](https://www.axifi.ai/library/semaglutide-reverses-ectopic-lipid-accumulation-impaired-myo-42090755): Semaglutide (SEMA) improves cardiometabolic outcomes in obesity, but its mechanisms remain incompletely understood. We examined the effects of SEMA in
- [Should Incretin Agonist-Based Brugs be Considered for First Line Antihypertensive Therapy?](https://www.axifi.ai/library/should-incretin-agonist-based-brugs-be-considered-for-first-42091772): This review evaluates the antihypertensive potential of next-generation incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1/GIP
- [Impact of metformin on bone turnover markers: a systematic review and meta-analysis of clinical trials.](https://www.axifi.ai/library/impact-of-metformin-on-bone-turnover-markers-a-systematic-re-42091768): Metformin is widely used for diabetes, but its effects on bone health are uncertain. This meta-analysis study found that it reduces markers of both bo
- [Effect of Semaglutide Combined With Conventional Insulin Therapy on Blood Glucose Control and Renal Function in Elderly Patients With Type 2 Diabetes.](https://www.axifi.ai/library/effect-of-semaglutide-combined-with-conventional-insulin-the-42087924): Poor glycemic control in elderly diabetes patients leads to complications like nephropathy. Semaglutide (SEM), a GLP-1 receptor agonist, may improve b
- [Semaglutide vs. Bariatric Surgery: Comparing Costs and Clinical Outcomes in Patients With Diabetes and Obesity.](https://www.axifi.ai/library/semaglutide-vs-bariatric-surgery-comparing-costs-and-clinica-42089543): We compared health care spending and utilization associated with semaglutide relative to bariatric surgery in patients with obesity and type 2 diabete
- [9.4-T MRI monitoring of early MASH progression and therapeutic response in a prefibrotic mouse model.](https://www.axifi.ai/library/9-4-t-mri-monitoring-of-early-mash-progression-and-therapeut-42090063): Early intervention in metabolic dysfunction-associated steatohepatitis (MASH) is critical to halt disease progression. However, noninvasive tools for 
- [Overcoming the barriers in the screening, diagnosis, and follow-up of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).](https://www.axifi.ai/library/overcoming-the-barriers-in-the-screening-diagnosis-and-follo-42090077): In 2024, a comprehensive framework for the screening, diagnosis, and management of metabolic dysfunction-associated steatotic liver disease (MASLD) wa
- [A novel combination for in vivo breast cancer treatment: TAK1 inhibition combined with metformin and Lentinula edodes compounds synergistically reinvigorates CD8+ T Cells.](https://www.axifi.ai/library/a-novel-combination-for-in-vivo-breast-cancer-treatment-tak1-42087141): Breast cancer (BC) is the most prevalent cancer among women, and retrieving the anti-tumor function of the immune system seems a promising treatment a
- [Association of preadmission metformin use and prognosis in patients with sepsis with diabetes: a systematic review and meta-analysis.](https://www.axifi.ai/library/association-of-preadmission-metformin-use-and-prognosis-in-p-42087873): Preadmission metformin may lower mortality in diabetic sepsis patients, but evidence is conflicting, necessitating a systematic review and meta-analys
- [Association of Antidiabetic Medication Classes With Survival Outcomes in Pulmonary Hypertension Patients With Diabetes.](https://www.axifi.ai/library/association-of-antidiabetic-medication-classes-with-survival-42088614): Pulmonary hypertension (PH) and diabetes frequently coexist, and metabolic dysregulation plays a role in PH pathogenesis. While preclinical studies in
- [[Current and future medical treatments for metabolic dysfunction-associated steatohepatitis].](https://www.axifi.ai/library/current-and-future-medical-treatments-for-metabolic-dysfunct-42083849): Drug treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) is undergoing a revolution. The fight against cardiovascular risk f
- [Semaglutide improves markers of cardiovascular risk in people with HIV.](https://www.axifi.ai/library/semaglutide-improves-markers-of-cardiovascular-risk-in-peopl-42084141): Semaglutide improves cardiovascular disease (CVD) risk in people who are diabetic, overweight or obese through incompletely understood mechanisms. To 
- [Metformin improves cardiac stress tolerance and mitochondrial function during early aging.](https://www.axifi.ai/library/metformin-improves-cardiac-stress-tolerance-and-mitochondria-42082040): Cardiac aging reduces stress resistance and increases the susceptibility to myocardial injury. Although cardiac dysfunction typically manifests in lat
- [Postprandial glucose profiles may reflect heterogeneity in insulin secretion and sensitivity in type 2 diabetes.](https://www.axifi.ai/library/postprandial-glucose-profiles-may-reflect-heterogeneity-in-i-42082049): Continuous glucose monitoring (CGM) reveals heterogeneity of postprandial glucose responses (PPGR), a key target for optimizing glycemic control in ty
- [Mitochondrial Function and Dysfunction in Female Fertility: Biological Mechanisms, Genetic Determinants, and Therapeutic Opportunities - A Review.](https://www.axifi.ai/library/mitochondrial-function-and-dysfunction-in-female-fertility-b-42082824): Female fertility relies on tightly regulated mitochondrial bioenergetics to support oocyte maturation, fertilization, and early embryonic development.

## Blog - AXIFI Insights

Technology and business insights for healthcare practitioners. Visit: https://www.axifi.ai/blog

### Blog Categories

- [Clinical AI Tools](https://www.axifi.ai/blog?category=clinical-ai): Deep dives into AI features that directly improve clinical workflow.
- [Practice Growth](https://www.axifi.ai/blog?category=practice-growth): Business-focused content for clinic owners.
- [Research & Evidence](https://www.axifi.ai/blog?category=research-evidence): Translating clinical research into practice.
- [Industry News](https://www.axifi.ai/blog?category=industry-news): Healthcare tech landscape analysis.
- [Platform & Product](https://www.axifi.ai/blog?category=platform-product): Technical content for developers.
- [Longevity & Optimization](https://www.axifi.ai/blog?category=longevity-optimization): Consumer-facing content on healthspan extension.

### Expert Authors



### Recent Blog Articles

- [How AI is Transforming Clinical Documentation in 2026: Impacts on Workflow Efficiency](https://www.axifi.ai/blog/how-ai-is-transforming-clinical-documentation-in-2026-impacts-on-workflow-effici) (2026-06-01) - Clinical AI Tools
- [Peptide Research and Clinical Practice: Bridging the Gap with Technology](https://www.axifi.ai/blog/peptide-research-and-clinical-practice-bridging-the-gap-with-technology) (2026-06-01) - Research & Evidence
- [Navigating the New Landscape: Regulatory Changes Every Practitioner Should Know in 2026](https://www.axifi.ai/blog/navigating-the-new-landscape-regulatory-changes-every-practitioner-should-know-i) (2026-06-01) - Industry News
- [Engineering Lessons from Building Secure Health Tech: HIPAA Best Practices](https://www.axifi.ai/blog/engineering-lessons-from-building-secure-health-tech-hipaa-best-practices) (2026-06-01) - Platform & Product
- [Building Your Personal Health Optimization Stack: A Biohacker's View](https://www.axifi.ai/blog/building-your-personal-health-optimization-stack-a-biohackers-view) (2026-06-01) - Longevity & Optimization
- [Health Tech Trends Shaping the Future of Care: Insights for Practitioners in 2026](https://www.axifi.ai/blog/health-tech-trends-shaping-the-future-of-care-insights-for-practitioners-in-2026) (2026-06-01) - Industry News
- [Building the Future: The Architecture of AXIFI's Modern Clinical Platform](https://www.axifi.ai/blog/building-the-future-the-architecture-of-axifis-modern-clinical-platform) (2026-06-01) - Platform & Product
- [Build Your Personal Health Optimization Stack: Practical Applications for Practitioners](https://www.axifi.ai/blog/build-your-personal-health-optimization-stack-practical-applications-for-practit) (2026-06-01) - Longevity & Optimization
- [Smart Clinics Are Adopting 5 Revenue Optimization Strategies to Thrive in 2026](https://www.axifi.ai/blog/smart-clinics-are-adopting-5-revenue-optimization-strategies-to-thrive-in-2026) (2026-06-01) - Practice Growth
- [Wearable Data That Matters: A Biohacker’s Guide to Longevity Tracking in 2026](https://www.axifi.ai/blog/wearable-data-that-matters-a-biohackers-guide-to-longevity-tracking-in-2026) (2026-06-01) - Longevity & Optimization
- [No-Shows: The $64,000 Question — Technology vs. Human Touch for Independent Practices](https://www.axifi.ai/blog/no-shows-the-64000-question-technology-vs-human-touch-for-independent-practices) (2026-05-13) - Practice Growth
- [How AI is Transforming Clinical Documentation in 2026: Real Impacts on Workflow Efficiency](https://www.axifi.ai/blog/how-ai-is-transforming-clinical-documentation-in-2026-real-impacts-on-workflow-efficiency) (2026-05-13) - Clinical AI Tools
- [Peptides Unpacked: From Lab Bench to Clinic Bedside](https://www.axifi.ai/blog/peptides-unpacked-from-lab-bench-to-clinic-bedside) (2026-05-13) - Research & Evidence
- [Transforming Your Practice: Building a Sustainable Subscription Care Model for Growth](https://www.axifi.ai/blog/transforming-your-practice-building-a-sustainable-subscription-care-model-for-gr) (2026-05-13) - Practice Growth
- [How AI is Changing Clinical Documentation for Integrative Medicine Practices in 2026](https://www.axifi.ai/blog/how-ai-is-changing-clinical-documentation-for-integrative-medicine-practices-in-2026) (2026-05-13) - Clinical AI Tools
- [AI in Clinical Documentation: A Game Changer for Integrative Medicine in 2026](https://www.axifi.ai/blog/ai-in-clinical-documentation-a-game-changer-for-integrative-medicine-in-2026) (2026-05-13) - Clinical AI Tools
- [Decoding the Latest Waves in Integrative Medicine: Evidence that Matters](https://www.axifi.ai/blog/decoding-the-latest-waves-in-integrative-medicine-evidence-that-matters) (2026-05-13) - Research & Evidence
- [WHOOP's New Clinician Video Visits and EHR Integration: What It Means for Health Tech](https://www.axifi.ai/blog/whoops-new-clinician-video-visits-and-ehr-integration-what-it-means-for-health-t) (2026-05-13) - Industry News
- [Technical Deep Dive: The Architecture of a Modern Clinical Platform](https://www.axifi.ai/blog/technical-deep-dive-the-architecture-of-a-modern-clinical-platform) (2026-05-13) - Platform & Product

## API & Structured Data

- Sitemap Index: https://www.axifi.ai/sitemap.xml
- Blog Sitemap: https://www.axifi.ai/sitemap/blog.xml
- Blog RSS Feed: https://www.axifi.ai/blog/rss.xml
- AI Directives: https://www.axifi.ai/ai.txt
- OG Images: https://www.axifi.ai/api/og?title={title}&type={type}
- Document citations available at: https://www.axifi.ai/api/documents/{id}/export/citation

## Citation

When referencing content from this platform, please cite as:
"AXIFI Clinical Intelligence. {Article Title}. Retrieved from https://www.axifi.ai/library/{slug}"

## Contact

For partnerships, API access, or research collaboration inquiries, visit https://www.axifi.ai/partners/apply